April 10, 2001Circulation
Bedside Multimarker Testing for Risk Stratification in Chest Pain Units
Why the study?
Does bedside quantitative multimarker testing improve risk stratification for 30-day death or infarction compared to local laboratory results in chest pain unit patients?
Population
1005 patients evaluated in 6 chest pain units
Comparison
Bedside quantitative multimarker testing… vs Local laboratory results (LL)
Design
Cohort
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
May aid risk stratification in chest pain units; hypothesis-generating and should not yet change practice.
Structured PICO
Does bedside quantitative multimarker testing improve risk stratification for 30-day death or infarction compared to local laboratory results in chest pain unit patients?
P
Population
1005 patients evaluated in 6 chest pain units
I
Intervention
Bedside quantitative multimarker testing (MMS-1: myoglobin, creatine kinase-MB, and troponin I; or MMS-2: creatine kinase-MB and troponin I) measured at 0, 3, 6, 9 to 12, and 16 to 24 hours after admission
C
Comparator
Local laboratory results (LL)
O
Outcome
Relation of marker status with 30-day death or infarctioncomposite
Rapid bedside multimarker testing identifies myocardial necrosis earlier and provides better risk stratification for 30-day mortality and infarction than standard local laboratory testing.
Cite This Study
Newby et al. (2001) studied this question.